Intensity Modulated Radiotherapy With Concomitant Boost in Breast Cancer

Scientific Institute for Research Hospitalization and Healthcare (IRCCS)

Status: Completed

Conditions: Breast Cancer; Radiation Toxicity

Treatments: Radiation: 3D-RT with sequential boost; Radiation: IMRT with concomitant boost

Study type: Observational

Funder types: Other

Identifiers

NCT03471741

MARA-2

Details and patient eligibility

About

To assess feasibility of postoperative IMRT with concomitant boost in moderate-high risk breast cancer in terms of late toxicity and local control

Full description

Patients treated conservatively with moderate-high risk breast cancer were treated with IMRT plus concomitant boost to surgical bed (up to a dose of 50 Gy to whole breast and 60 Gy to the tumor bed).

Aim of the study was to evaluate late toxicity and local control after this treatment compared with a historical control group (CG) of patients treated with 3D-conformal postoperative radiotherapy delivered with conventional fractionation.

Enrollment: 451 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• histologically confirmed invasive breast cancer (pT1-4) with at least one of these characteristics: 3 or more metastatic axillary nodes, pre or peri-menopausal status, close resection margins
• breast conservative surgery

Exclusion criteria

• positive margins
• distant metastases

Trial design

451 participants in 2 patient groups

MARA-2: IMRT with concomitant boost

Description:

A forward planned IMRT technique was used and the prescribed dose to the whole breast was 50 Gy plus a concomitant boost of 10 Gy to the tumor bed

Treatment:

Radiation: IMRT with concomitant boost

CG: 3D-RT with sequential boost

Description:

The whole breast received 50.4 Gy in 28 fractions delivered with 3D-RT, followed by a sequential boost on the tumor bed of 10 Gy in 4 fractions delivered with electrons

Treatment:

Radiation: 3D-RT with sequential boost